Andrew Berens, an analyst from Leerink Partners, maintained the Buy rating on Tango Therapeutics (TNGX – Research Report). The associated price target remains the same with $10.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Berens has given his Buy rating due to a combination of factors that highlight Tango Therapeutics’ promising developments and strategic focus. The company has reported a confirmed overall response rate of 43% in cholangiocarcinoma for its TNG462 therapy, and upcoming updates are expected to provide further insights into its efficacy in larger indications such as pancreatic cancer and non-small cell lung cancer (NSCLC). The anticipated update in the second half of 2025 will include data from a significant number of patients, which could demonstrate the potential success of a pivotal trial planned for 2026.
Additionally, Tango Therapeutics has shown a median progression-free survival of 24 weeks across various tumor types, which is a notable improvement over the current standard of care in second-line pancreatic cancer. This data could help mitigate concerns about the durability of their treatment outcomes. The company’s strategic decision to focus on key clinical developments and optimize capital allocation further supports the positive outlook. These factors collectively contribute to Berens’s confidence in Tango Therapeutics’ growth potential and justify the Buy rating.
In another report released yesterday, Barclays also maintained a Buy rating on the stock with a $13.00 price target.